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ABSTRACT 
A simple reverse-phase HPLC method for the estimation of Azelastine hydrochloride in nasal spray formulations has been developed. The 
method is simple, accurate, precise, specific and linear over the analysis range. This developed method has been validated according to 
International Conference on Harmonization (ICH) guideline with respect to system suitability, specificity, precision, linearity, accuracy, and 
robustness. An isocratic condition of mobile phase comprising Phosphate buffer (pH 3.1): Acetonitrile in a ratio of 60:40, v/v at a flow rate of 
1.0 mL/minute over RP C18 (octadecylsilane (ODS), 250 × 4.6 mm, 5 µm, CHROMOSIL) column at ambient temperature was maintained. 
Besides, the chromatographic peak was observed sharp & symmetric. The proposed method was successfully applied for the estimation of 
the Azelastine hydrochloride in nasal spray formulation. 
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INTRODUCTION 
Inflammation mostly occurs due to an allergic reaction, and 
people who suffer from nasal allergies, such as hay fever, 
dust and mite, tend to experience a variety of symptoms 
due to this 
Inflammation1. Inflammation is not a synonym 
for infection. Infection describes the interaction between 
the action of microbial invasion and the reaction of the 
body's inflammatory response2. Simply, Inflammation is 
part of the body's immune response. Inflammation of the 
nasal passage forces fluid out of the nasal tissues, resulting 
in a runny and blocked nose. Other symptoms include 
interfere with hearing and speech, sneezing, watery and 
itchy eyes. 
The three main types of drugs available for anti-
inflammatory and anti-allergic effect are corticosteroids, 
antihistamines3 and decongestants. Corticosteroid drugs 
include budesonide, flunisolide, fluticasone furoate, 
fluticasone propionate and mometasone furoate, 
antihistamine drugs include azelastine and olopatadine . 
Two common decongestants available in the nasal sprays 
or drops form are oxymetazoline and phenylephrine. 
Azelastine hydrochloride is an antihistamine formulated as 
a metered-spray solution for intranasal administration. It 
works by blocking certain natural substances called 
histamines that are responsible for nasal symptoms. 
This medication issued to relieve nasal symptoms such as 
runny/itching/stuffy nose, sneezing, and post-nasal drip 
caused by allergies or other conditions 1.   
Azelastine has a triple mode of action: Anti-
histamine effect, Mast-cell stabilizing effect and Anti-
inflammatory effect4. 
Its chemical name is (±)-1-(2H)-phthalazinone,4-
[(4chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-
azepin-4-yl)-, monohydrochloride. Its molecular formula is 
C22H24ClN3O•HCl with the following chemical structure:  
 
Figure 1: Chemical structure of Azelastine 
hydrochloride 
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Azelastine hydrochloride occurs as a white, almost 
odorless, crystalline powder with a bitter taste. It has a 
molecular weight of 418.37. It has a melting point of about 
225 °C. It is sparingly soluble in water, methanol, and 
propylene glycol5.  
In current scenario, official method for quantification of 
Azelastine hydrochloride is available and that is of 
titrimetric method6 which is highly sensitive and time 
consuming, but accurate and precise reverse phase HPLC 
method is not available. Our interest of work was to 
develop suitable and rapid HPLC method required for 
analysis and characterization of Azelastine hydrochloride 
from nasal spray formulation. 
2. MATERIALS AND METHODS 
2.1 Materials and Reagents 
Azelastine hydrochloride working standard and Placebo 
were a kind gift of Shree Industrial Training Centre And 
Research Laboratory, Jalgaon, Maharashtra. Test samples 
purchased from market store. HPLC grade Acetonitrile, 
Potassium dihydrogen phosphate and HPLC Water were 
purchased from Ranbaxy Fine Chemicals Ltd., India. 
2.2 HPLC system 
High-performance  liquid  chromatographic  system  
(Younglin ( S.K) Gradient System) and  equipped  with  UV–
visible  detector was  used  for  the analysis. The data were 
recorded using Autochro -3000 software.  
2.3 Preparation of mobile phase 
Dissolved 6.8 gm of KH2PO4 in to 1000 ml water and 
sonicated to dissolved (pH observed 4.42), adjusted to pH 
3.10 with diluted Orthophosphoric acid solution. Buffer 
filtered through a 0.45-µm PVDF membrane filter and 
sonicated to degas. Prepared a mixture of Buffer (pH 3.1) : 
Acetonitrile (60:40), v/v, sonicated to degas. 
2.4 Preparation of standard solution (50 PPM) 
Accurately weighed and transferred 50 mg of Azelastine 
hydrochloride working standard in to 100 mL volumetric 
flask, added about 30 mL of  Acetonitrile and sonicated to 
dissolve, wait to cool and diluted up to mark with diluent. 
Transferred 5 mL of this solution in to 50 mL volumetric 
and diluted up to mark with Mobile Phase. 
2.5 Preparation of sample solution (50 PPM) 
Brand Name:- ARZEP( CADILA HEALTH CARE)  
Transferred 2.5 mL of Sample solution in to 50 mL 
volumetric flask, added about 30 mL of mobile phase and 
sonicated to mixed properly, diluted up to mark with 
mobile phase, and the samples were analyzed using the 
proposed analytical methods. 
2.6 Chromatographic conditions 
The analysis was carried out at ambient temperature 
under isocratic condition. The mobile phase was run at  a  
flow  rate  of  1.0  mL/minute  for  10  min.  The injection 
volume was 20 µL for standard and samples. Before 
analysis, every standard and sample was filtered through 
0.45 µm Nylon syringe filter. The column eluent was 
monitored with UV detection at 239 nm7. 
2.7 Method validation   
Validation of an analytical procedure is the process by 
which it is established by laboratory studies, that the 
performance characteristics of the procedure meet the 
requirements for the intended analytical applications. The 
objective of validation of an analytical procedure is to 
demonstrate that it is suitable for its intended purpose.  
Typical parameters verified in validation of analytical 
method are listed in table 1. ICH Q2(R1)8  is  considered  
the  primary  reference  for  recommendations  and  
definitions  on  validation characteristics for analytical 
procedures. 
Table 1: Typical parameters verified in method 
validation 
Sr No Validation parameter 
1 System suitability 
2 Specificity 
3 Precision 
4 Accuracy 
5 Linearity 
6 Robustness 
2.7.1 System suitability 
System suitability test as an integral part of method 
development was used to ensure adequate performance of 
the chromatographic system. To determine system 
precision Azelastine Hydrochloride standard solution was 
prepared and injected for six times into HPLC system. The 
mean, SD and % RSD for peak areas of Azelastine was 
calculated.  
2.7.2 Specificity 
The ICH documents define specificity as the ability to 
assess unequivocally the analyte in the presence of 
components that may be expected to be present, such as 
impurities, degradation products and matrix components. 
The placebo solution containing excipients without 
Azelastine were injected. 
 To evaluate the specificity of the method blank, placebo 
and test solution were injected. 
2.7.3 Precision 
The precision of an analytical procedure is the degree of 
agreement among individual test results when the 
procedure is repeatedly applied to multiple samplings of a 
homogeneous sample. The precision of an analytical 
procedure is usually expressed as the standard deviation 
or relative standard deviation (coefficient of variation) of a 
series of measurements. Precision may be a measure of 
either the degree of reproducibility  or  of  repeatability  of  
the  analytical  procedure  under  normal  operating  
conditions. The precision of the assay method was 
assessed with respect to repeatability and reproducibility. 
The  precision of  the  proposed  method was checked by 
ability of  responses  after  replicate injections and  
expressed as %RSD  among responses using the formula. 
Sample of a single batch were prepared six times and 
analyzed as per test method, % assay of Azelastine for six 
samples calculated for method precision. 
2.7.4 Accuracy 
The accuracy of an analytical procedure is the closeness of 
test results obtained by that procedure to the true value.  
The accuracy of an analytical procedure should be 
established across its range. In the present study, 
successive analysis (n=3) for three different 
concentrations of standard mixtures (50, 100 and 150%) 
was carried out to determine the accuracy of proposed 
method. 
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2.7.5 Linearity 
Linearity was checked on different concentrations within 
50–200% of the nominal standard concentration. The 
linearity of the proposed method was evaluated by using 
calibration curve to calculate the coefficient of correlation, 
slope, and intercept values. 
2.7.6 Robustness 
Robustness is an indication of the reliability of the 
analytical method during normal usage. The effect of the 
following deliberate changes in chromatographic 
conditions was monitored: Detector wavelength±2 nm, 
Flow rate±10%, Temperature±2 °C, and pH of Buffer 
solution±0.1. 
3. RESULTS AND DISCUSSION 
3.1 System suitability 
The results of system suitability were within acceptable 
limits as shown in table 2. 
 
 
Table 2:  Results  from  the  determination  of  system  
precision  for  determination  of  Azelastine 
Standard No Peak area of Azelastine 
1 1233 
2 1256 
3 1240 
4 1242 
5 1249 
6 1239 
Mean 1243 
SD 8.13 
%RSD 0.65 
Values are expressed for six replicate (n=6) 
Table 3: System suitability data from Method precision 
Sample No % Assay of Azelastine 
1 99.7 
2 99.3 
3 99.7 
4 100.2 
5 100.1 
6 99.3 
Mean 99.7 
SD 0.35 
% RSD 0.35 
Values are expressed as mean± standard deviation of six 
samples (n=6)
 
3.2 Specificity 
a) Blank 
 
 
b) Placebo
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c) Sample solution 
 
Figure 2: HPLC Chromatogram a) Blank, b) Placebo and c) Sample solution 
 
3.3 Accuracy 
Known amount of Azelastine hydrochloride was spiked in 
placebo at about 50,100 and 150% of test concentration. 
The amount of Azelastine hydrochloride recovered was 
quantified as per developed method.  The % recovery was 
calculated from the amount found and actual amount 
added. The results are tabulated in table 4.  The overall 
recovery of Azelastine hydrochloride in the samples was in 
between 98.0 to 102.0% (RSD<2%) which is sufficient for 
quantification of Azelastine hydrochloride in nasal spray 
formulations.
 
Table 4: Evaluation of accuracy of the proposed method for quantification of Azelastine 
Spiked level (%)/ 
Sample No 
Actual amount of 
API added(mg) 
Amount of Azelastine  
found (mg) 
% Recovery Mean SD %RSD 
50% Sample-1 1.2549 1.2532 99.9  
 
99.8 
 
 
0.33 
 
 
0.33 
50% Sample-2 1.2549 1.2472 99.4 
50% Sample-3 1.2549 1.2552 100.0 
100% Sample-1 2.5098 2.4964 99.5  
 
99.4 
 
 
0.22 
 
 
0.22 
100% Sample-2 2.5098 2.4894 99.2 
100% Sample-3 2.5098 2.5004 99.6 
150% Sample-1 3.7646 3.7436 99.4  
 
99.4 
 
 
0.10 
 
 
0.10 
150% Sample-2 3.7646 3.7376 99.3 
150% Sample-3 3.7646 3.7446 99.5 
Values are expressed as mean± standard deviation of replicate (n=3) 
 
3.4 Linearity 
A graph was plotted with concentration (in µg/ml) of 
Azelastine hydrochloride on X-axis and peak areas of 
Azelastine on Y-axis. The results are tabulated in table 5 
and graphically represented in figure 3. The method 
showed excellent linear response with correlation 
coefficient (R2) values of 0.999, which was within the limit 
of the correlation coefficient (R2=0.995). 
 
Figure 3: Linearity plot for Azelastine 
 
 
Figure 4: Overlay graphs of linearity plot. 
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Table 5: Results of linearity 
Spike level in % Concentration (mcg/mL) Average Area (N=2) 
50 25.10 622 
80 40.16 995 
100 50.20 1245 
150 75.29 1850 
200 100.39 2478 
Slope 24.59 
Y-Intercept 6.24 
Correlation Coefficient ® 0.99998 
 
5 Robustness results 
Robustness of the method was verified by deliberately 
varying the following chromatographic conditions as 
shown in table 5 i.e. 
 By changing the wavelength by±2 nm 
 By changing the flow rate by±10% 
 By changing the column oven temperature by±2 °C 
 By changing the pH of buffer used for mobile phase by 
to±0.1 unit 
 
Table 6: Robustness experiment 
Sr. 
No. 
Robustness Parameter Retention 
Time (min) 
Tailing 
factor 
Theoretical 
plates 
% RSD of  Standard 
solution 
1 Wavelength 237 nm 2.98 1.3 4268 0.17 
2 Wavelength 241 nm 2.98 1.3 4170 0.23 
3 Flow rate (0.90 mL/min) 3.04 1.3 4527 0.10 
4 Flow rate (1.10 mL/min) 2.88 1.2 4649 0.06 
5 Column Temp 28° C 2.98 1.3 4200 0.11 
6 Column Temp 32° C 2.98 1.3 4270 0.34 
7 Buffer pH 3.0 2.98 1.2 3819 0.17 
8 Buffer pH 3.2 2.98 1.2 3945 0.11 
 
3.6 Estimation of formulations 
The assay values of Azelastine hydrochloride in nasal spray 
formulations ranged from 99. % to 100.2%, with a 
standard deviation of not more than 0.35%.  The assay 
values for the formulations were same as mentioned in the 
label claim, indicating the suitability of the proposed 
analytical method.  The estimated drug content with low 
values of standard deviation established the precision of 
the proposed method. 
3.7 DISCUSSION 
Development  of  an  analytical  method  for  assessment  of  
drugs  in  the  pharmaceutical  dosage  form  is  of utmost  
necessity to confirm  the  quality of  nasal formulations 
with respect to assay6 and spray  content uniformity.  
Our developed HPLC analytical method for estimation of 
Azelastine in nasal spray formulations has used very less 
amount of organic solvents which is cost effective and 
environment friendly. Also, the method was found to be 
simple and accurate and was able to resolve the drug from 
excipients in a short analytical run time. 
4.0 CONCLUSIONS 
A simple reversed-phase HPLC method for the analysis of 
Azelastine hydrochloride in nasal spray formulations was 
developed and validated. The proposed method is simple, 
accurate, precise, specific and linear over the analysis 
ranges and was able to resolve the drug from excipients in 
a short analytical run time. 
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